According to the latest financial report of Medigus C/Wts 23/07/2023(To Pur Ads)Series C, the latest earnings per share (TTM) for the company is --. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Medigus C/Wts 23/07/2023(To Pur Ads)Series C's free cash flow? The latest report shows it as -1.22M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Medigus C/Wts 23/07/2023(To Pur Ads)Series C shows that the company's current ratio is 1.39, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Medigus C/Wts 23/07/2023(To Pur Ads)Series C, the quick ratio is 1.31, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Medigus C/Wts 23/07/2023(To Pur Ads)Series C? The latest ROE figure is -9.91%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Medigus C/Wts 23/07/2023(To Pur Ads)Series C, the total asset return on investment (ROA) is -7.09%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Medigus C/Wts 23/07/2023(To Pur Ads)Series C's latest financial report to see how their gross margin is doing - currently at 7.14%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Medigus C/Wts 23/07/2023(To Pur Ads)Series C, the net profit margin is -856.12%, which is a good sign for its profitability.